Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.30 |
| ▸ | HTR2A | P28223 | 2/20 | 0.30 |
| ▸ | DRD3 | P35462 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18966673 | 0.95 | — | — | |
| SCHEMBL18966777 | 0.94 | NAMPT (0.33) | DRD2HTR2ADRD3 | |
| SCHEMBL18966545 | 0.93 | NAMPT (0.33) | — | |
| SCHEMBL18966898 | 0.93 | PRKCB (0.30) | — | |
| SCHEMBL18966992 | 0.92 | — | — | |
| SCHEMBL18966905 | 0.92 | — | — | |
| SCHEMBL18966996 | 0.92 | MTNR1A (0.34) | — | |
| SCHEMBL18966541 | 0.92 | MEN1 (0.33) | — | |
| SCHEMBL18966551 | 0.92 | PRKCB (0.33) | — | |
| SCHEMBL18966678 | 0.91 | NAMPT (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10464952-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2019-11-05 | — | — | US | disclosed |
| WO-2017100537-A1 | BETA-LACTAMASE INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2017-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10464952-B2 | Beta-lactamase inhibitors | MGAM, GAA, LCT | DRD2 3783/4885HTR2A 3376/4885DRD3 3584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.